Grace Patterson
Research Scientist at Crescendo Biologics Limited | United Kingdom
Grace Patterson’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
Research Scientist at Crescendo Biologics Limited in February 2024 - Present
Research Assistant -Discovery at Crescendo Biologics Limited in June 2022 - March 2024
Genetic Technologist at Oncologica UK in July 2021 - April 2022
University of Kent, Bachelor of Science - BSc, January 2018 to January 2021
Rainham Mark Grammar School, January 2016 to January 2018
Chatham Grammar School For Girls, January 2011 to January 2016
Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical candidate from Crescendo’s T cell enhancing pipeline. Crescendo is also developing CB213, a preclinical PD-1 x LAG-3 multi-specific Humabody. The Company’s ability to develop multi-functional Humabody therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human VH domain building blocks (Humabody VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody-based formats can also be applied across a range of non-cancer indications. Beyond Crescendo’s proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody), which is expected to enter global Phase 2 clinical development in patients with psoriasis. Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital. For more information, please visit www.crescendobiologics.com.
Discover more about Crescendo Biologics LimitedSenior Project Manager at Crescendo Biologics
Senior Project Manager, Early Stage R&D at Crescendo Biologics Limited
(March 2022 – Present)
Research Scientist at Crescendo Biologics Ltd (Translational Team) | MSc (Med), with skills in Molecular Biology, Immunology, and Genetics
Research Associate at Crescendo Biologics Limited
(May 2022 – Present)
Research Associate at Crescendo Biologics
Research Associate at Crescendo Biologics Limited
(August 2021 – Present)
Laboratory Analyst
Research Assistant at Crescendo Biologics Limited
(May 2022 – Present)
Research Assistant at Crescendo Biologics
Research Assistant at Crescendo Biologics Limited
(August 2023 – Present)
Senior Scientist at Crescendo Biologics Limited
Principal Scientist at Crescendo Biologics Limited
(February 2024 – Present)
What is Grace Patterson email address?
Email Grace Patterson at [email protected] and [email protected]. This email is the most updated Grace Patterson's email found in 2026.
How to contact Grace Patterson?
To contact Grace Patterson send an email to [email protected] or [email protected].
What company does Grace Patterson work for?
Grace Patterson works for Crescendo Biologics Limited.
What is Grace Patterson's role at Crescendo Biologics Limited?
Grace Patterson is Research Scientist